The drugs we've got...the drugs we're getting...beyond blood. A three-part look at the Fourth Conference on Retroviruses and Opportunistic Infections.
Mascolini
M
M
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004279:DNA, Viral; D004352:Drug Resistance, Microbial / Q000235:genetics; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D008221:Lymphoid Tissue; D009093:Mucus / Q000821:virology; D009154:Mutation; D010349:Patient Compliance; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D012661:Semen / Q000821:virology; D016896:Treatment Outcome; D014621:Vagina / Q000378:metabolism; D019562:Viral Load
D019380:Anti-HIV Agents; D004279:DNA, Viral; D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors